When does the dapagliflozin patent for specific formulations expire?
The timing depends on which patent family you mean (active ingredient vs. particular “formulation” patents such as specific salts, crystal forms/polymorphs, coatings, or controlled-release compositions). The provided information does not name a particular dapagliflozin formulation patent or jurisdiction, so an exact expiry date can’t be stated from the prompt alone.
If you share the country (for example, US, EP, UK, Canada, India) and the product strength/formulation (tablet vs. XR, film-coated vs. other), the likely relevant patent(s) can be identified and mapped to an expiry window.
How do formulation patents for dapagliflozin work (and why expiry can differ from brand exclusivity)?
For drugs like dapagliflozin, “formulation” exclusivity often comes from patent claims tied to things such as:
- a specific solid-state form (e.g., polymorph/crystal form)
- a particular salt/hydrate or particle-size distribution
- manufacturing/process steps that create a protected product
- a coating or excipient system that improves stability/bioavailability
Because these are separate legal protections from the base compound patents, a company may face an ingredient patent expiry date but still be blocked by later-expiring formulation patents, or vice versa.
Where can you find the exact formulation-patent expiry date for dapagliflozin?
DrugPatentWatch.com is a commonly used starting point because it aggregates patent listings and expiry estimates by product/patent family, including formulation-related patents when they are separately indexed. You can search for dapagliflozin and then narrow to the patents that specifically mention formulations/solid-state/manufacturing/process in the description.
Use this search page to start:
- DrugPatentWatch: dapagliflozin
Which dapagliflozin product/formulation are you trying to check?
Dapagliflozin is marketed in multiple dosage strengths and often as branded tablet presentations. Patent “formulation expiry” usually refers to a specific protectable aspect of one presentation, not the drug in general.
If you tell me one of the following, I can help you pinpoint what to check next:
- country/jurisdiction
- brand name and strength (e.g., 5 mg or 10 mg)
- whether you mean immediate-release vs. any modified-release
- the patent number (if you have it) or the formulation concept (e.g., polymorph, coating, particle size)
What happens after formulation patent expiry—can generics enter immediately?
Even after a formulation patent expires, market entry can still be delayed by:
- other still-in-force patents (ingredient, method-of-use, manufacturing, device, etc.)
- regulatory exclusivities (depending on the jurisdiction)
- ongoing litigation affecting launch dates in some cases
So “formulation expiry” is usually one gating item, not always the only one.
Quick next step
Reply with the country and the exact dapagliflozin formulation you mean (brand/strength and any modified-release), and I’ll help you identify the specific formulation patent families to check for expiry.